secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001493152-24-036380
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.01, 5.02, 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed deconsolidates Lucid Diagnostics, expects ~$70M gain; faces Nasdaq delisting, appoints new director
--------------------------------------------------------------------------------

- Deconsolidated Lucid from financials; expects ~$70M non-cash gain in Q3 2024.
- Pro forma stockholders' equity improves $9.7M but still deficit of ~$9.0M.
- Received Nasdaq delisting notice for failing min market value; will appeal with hearing in Oct.
- Dr. Cox and Harvey resigned from board; Dr. Agrawal appointed as Class B director.
- PAVmed retains 31.3M Lucid shares (no change); deconsolidation does not affect ownership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315224036380/0001493152-24-036380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315224036380/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-036380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer